Results of long term iron chelation treatment with deferoxamine.
Davis
Bernard A
BA
Department of Haematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK.
Porter
John B
JB
D003676:Deferoxamine / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D007758:Ear, Inner / Q000187:drug effects; D004700:Endocrine System Diseases / Q000188:drug therapy / Q000209:etiology; D005123:Eye / Q000187:drug effects; D006331:Heart Diseases / Q000188:drug therapy / Q000209:etiology; D049673:History, 20th Century; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use*; D019190:Iron Overload / Q000150:complications / Q000188:drug therapy* / Q000266:history / Q000378:metabolism; D013789:Thalassemia / Q000150:complications / Q000188:drug therapy; D013997:Time Factors
D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine